Live: Hims Reports Q1 Earnings Tonight. Can the Recovery Continue?

Live Updates

Four Big Wildcards Heading Into HIMS Q1 Earnings Tonight

7 minutes ago

Live

Four Wildcards Not Priced Into Tonight’s Earnings Report

1. The Novo settlement aftermath. The March Novo Nordisk settlement halted compounded GLP-1 sales, baking in a $65 million revenue headwind. Any color on branded Wegovy distribution talks is the swing factor.

2. Eucalyptus deal status. The pending ~$450M ARR acquisition, which expands into Australia and Japan, sits outside 2026 guidance. Closing timeline is unmodeled upside.

3. CFO selling. Oluyemi Okupe disposed 114,549 shares in April at prices up to $29.96, a flag against the rally.

4. Crowd vs. insiders. Polymarket prices just a 15.5% probability of a beat against 35% short interest, setting up an asymmetric squeeze if Hims & Hers (NYSE:HIMS) clears the $0.03 bar.

Strong Q1 Earnings Would Support HIMS's 45% Rally

48 minutes ago

Live

After falling roughly 45% over the past year, $HIMS rebounded about 45% in the past month as sentiment improved and expectations reset higher. Now the market needs proof the recovery is backed by fundamentals, not just momentum.

This quarter likely comes down to three things: revenue landing at or above guidance, stabilizing margins, and a credible path toward stronger cash flow generation. If management delivers across those areas, investors may start viewing the rally as the beginning of a broader rerating.

The risk is that expectations have already run ahead of the stock price. At roughly 26x forward earnings, weak guidance, softer growth, or continued margin pressure could quickly reopen the debate around whether the rebound ran ahead of the business fundamentals.

Investors are watching Hims & Hers (NYSE:HIMS) ahead of its first-quarter results due today after the close. After a 45.8% rally in the last month, expectations have reset sharply.

A Rally Built on GLP-1 Optimism

Last quarter, the telehealth platform delivered $617.82M in revenue, up 28.41% year over year, and adjusted EPS of $0.08, beating the $0.05 estimate. Subscribers crossed 2.5 million, with monthly revenue per subscriber climbing to $83.

Since the company’s Q4 report, shares have rebounded hard. A GLP-1 expansion announcement on April 23 and RFK Jr.’s commentary on peptide policy reignited retail interest. Management also guided for full-year 2026 revenue to $2.7B to $2.9B and adjusted EBITDA to $300M to $375M, anchored on continued compounded semaglutide access.

Guidance and YoY Setup

Margins, Cash Flow, and the GLP-1 Question

I’ll be watching three numbers closely. First, gross margin. It compressed roughly 500 basis points to 72% in Q4 due to international scaling and lower shipping costs. It will be exciting to see if management shows that the trajectory is stabilizing here.

Second, free cash flow. It swung to negative $2.57M in Q4 as capex jumped 137.61% to $63.88M on pharmacy automation. With roughly $1B in convertible debt from the May 2025 offering, the cash conversion story matters.

Third, compounded semaglutide. Guidance explicitly assumes continued access. Any FDA or political shift on that program reshapes the model fast. Investors will look for any details on the pending Eucalyptus acquisition (Australia and Japan, ARR around $450M) and the ZAVA Europe deal, both of which underpin the $1B international revenue target within three years.

The crowd is bracing for trouble. Polymarket pegs the probability of an earnings beat at just 8.5%, while analyst consensus price targets are $26.04, versus a stock price of $30.12.